Overview
Publication
Vaccine. 2018 Feb 21; 36(9):1235-1242.
PubMed ID: 29395528
Title
Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention
Authors
Thiam-Diouf A, Metch B, Sharpec C, Mulugetad R and Andrasik MP
Abstract
The primary objectives of HIV Vaccine Trials Network (HVTN) phase 1 preventive HIV vaccine clinical trials are to assess safety and immune response to study products. Participant alcohol and drug use may affect adherence, retention, and risk of HIV infection. Data on the effects of substance use are limited to medical care compliance and treatment adherence in HIV infected participants. To our knowledge, there are no data assessing substance use and retention in these vaccine trials.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.